Skip to Content
Merck
All Photos(1)

Documents

235296

Sigma-Aldrich

2-(Trifluoromethyl)phenylacetic acid

98%

Synonym(s):

(α,α,α-Trifluoro-o-tolyl)acetic acid

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Linear Formula:
CF3C6H4CH2CO2H
CAS Number:
3038-48-0
Molecular Weight:
204.15
EC Number:
221-240-4
MDL number:
MFCD00004327
UNSPSC Code:
12352100
PubChem Substance ID:
24854094
NACRES:
NA.22

Quality Level

100

Assay

98%

form

solid

mp

100-102 °C (lit.)

SMILES string

OC(=O)Cc1ccccc1C(F)(F)F

InChI

1S/C9H7F3O2/c10-9(11,12)7-4-2-1-3-6(7)5-8(13)14/h1-4H,5H2,(H,13,14)

InChI key

TYOCDHCKTWANIR-UHFFFAOYSA-N

Related Categories

Application

2-(Trifluoromethyl)phenylacetic acid has been used in the synthesis of potential antithrombotics and lipoxygenase inhibitors.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H315,H319,H335

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

E S Lazer et al.
Journal of medicinal chemistry, 33(7), 1892-1898 (1990-07-01)
A series of 2,6-disubstituted 4-(2-arylethenyl)phenols with potent human neutrophil 5-lipoxygenase (5-LO) inhibiting activity (IC50S in the 10(-7) M range) and weaker human platelet cyclooxygenase (CO) inhibiting activity (IC50S in the 10(-6) M range) is described. This series evolved from the
P L Barker et al.
Journal of medicinal chemistry, 35(11), 2040-2048 (1992-05-29)
Stimulation of platelets activates GPIIbIIIa, the heterodimeric integrin receptor, to bind fibrinogen (Fg), which results in platelet aggregation. GPIIbIIIa/Fg binding inhibitors are potentially suitable for acute use during and after thrombolytic therapy as antithrombotic agents. Incorporation of the tripeptide sequence

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service